Skip to main content
NCBI home page
Elsevier Sponsored Documents logoLink to Elsevier Sponsored Documents
. 2019 Dec;74:100650. doi: 10.1016/j.jbior.2019.100650

MicroRNAs and their involvement in T-ALL: A brief overview

Nádia C Correia a,b,∗, João T Barata c,∗∗
PMCID: PMC6899521  PMID: 31548132

Abstract

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy in which the transformed clone is arrested during T-cell development. Several genetic and epigenetic events have been implicated in this transformation. MicroRNAs (miRNAs) are small, non-coding RNAs that primarily function as endogenous translational repressors of protein-coding genes. The involvement of miRNAs in the regulation of cancer progression is well-established, namely by down-regulating the expression of key oncogenes or tumor suppressors and thereby preventing or promoting tumorigenesis, respectively. Similar to other cancers, several miRNA genes have been identified and implicated in the context of T-ALL. In this review we focused on the most studied microRNAs associated with T-ALL pathogenesis.

Keywords: T-ALL, microRNAs, Leukemia, OncomiRs, Tumor supressor miRNAs

Acute lymphoblastic leukemia (ALL) is a hematological cancer originated from the malignant transformation of a lymphoid precursor that is blocked at an immature stage of differentiation. ALL can arise in T- or B-cell precursors, hence being classified as T-ALL or B-ALL, respectively, which can be further subdivided according to specific genetic abnormalities (Pui and Evans, 2013; Pui et al., 2004).

T-ALL is characterized by the recurrent over-expression of a specific set of transcription factors, namely TLX1, TLX3, TAL1, LMO, HOXA, LYL1 and NKX family members, each defining a distinctive gene expression signature that identifies molecular subtypes in T-ALL (Belver and Ferrando, 2016; Ferrando et al., 2002; Homminga et al., 2011). Translocations leading to the activation of a small number of oncogenes occur in 25–50% of T-ALL cases. Other genetic abnormalities include frequent micro-deletions leading to the loss of tumor suppressor genes (Clappier et al., 2006; Graux et al., 2006; Hebert, 1994). The events driving a full malignant phenotype in T-ALL include also over-expression of oncogenes, defects in the cell cycle control, gain of function mutations in cytokine receptors (Oliveira et al., 2019) and tyrosine kinases (Bains et al., 2012; Oliveira et al., 2017), and activating mutations of NOTCH1(Atak et al., 2013; Weng et al., 2004).

1. MicroRNAs and leukemia

MicroRNAs (miRNAs) - the most studied class of non-coding RNAs – are small, 19–22 nt long, single stranded RNAs that provide post-transcriptional control of gene expression. In mammals, miRNAs function mostly as endogenous translational repressors of protein-coding genes through sequence-specific binding to the 3′-untranslated region (3′UTR) of a target messenger RNA (Bartel, 2004; Lim et al., 2005). The differential expression of microRNAs in hematopoiesis suggested early on that their deregulation could have a role in leukemogenesis (Chen et al., 2004). Initial reports of microRNA expression profiles revealed that miRNA gene expression signatures could be used to distinguish cancer types, including leukemia (Fulci et al., 2009; Lu et al., 2005; Mi et al., 2007; Schotte et al., 2009). In fact, the initial evidence for the involvement of miRNAs in cancer came from the molecular characterization of the 30 kb deletion 13q14 in human chronic lymphocytic leukemia (CLL). This genomic region harbors the miR15 and miR16 genes that were found to be deleted or down-regulated in the majority of CLL patients (Calin et al., 2002). Both microRNAs from this cluster negatively regulate BCL2, inducing apoptosis in leukemic cells (reviewed in (Pekarsky and Croce, 2019).

Importantly, leukemia signatures should be framed in light of the microRNA variations that occur during normal hematological development (Fabbri et al., 2009). Currently, the involvement of miRNAs in leukemogenesis is well established and different miRNAs have been identified as oncogenes or tumor suppressors in human leukemia. Moreover, microRNA expression signatures can be used not only to classify human acute lymphoblastic leukemia but also to predict prognosis, namely CNS involvement (Zhang et al., 2009), risk of relapse (Zhang et al., 2009) and relapse-free survival (Han et al., 2011; Schotte et al., 2011).

2. MicroRNAs and T-ALL

The participation of miRNA genes, individually or as part of a network, has been implicated in the pathogenesis of T-ALL.

Initial studies concluded that, contrary to B-ALL subtypes (Fulci et al., 2009), hierarchical clustering and principal component analysis of the expression levels of 430 miRNAs in 50 clinical T-ALL specimens did not distinguish between the major cytogenetic groups (HOXA, TAL or LMO and TLX1 or TLX3), which differ by few miRNAs (Mavrakis et al., 2010). Nevertheless, in the high-risk subgroup of Early T-cell precursor ALL (ETP-ALL), the microRNAs miR-221 and miR-222 were found significantly up-regulated when compared to non-ETP-ALL cases (Coskun et al., 2013). Moreover, it has been proposed that miR-222 may, to some extent, contribute to the myeloid character of ETP-ALL by down-modulating ETS1 expression. The authors hypothesized also that the fact that ETP-ALL cases failed to respond to standard intensive chemotherapy and displayed poor prognosis in initial studies, could be due to the actions of miR-222. This is because miR-222, by significantly inhibiting proliferation and causing cell cycle arrest, might not only partially explain the stem-like character of ETP-ALL but also counteract the efficacy of standard chemotherapy directed to actively cycling cells (Coskun et al., 2013). In addition, miR-221 associates with poor prognosis: increased expression correlates significantly with lower 5-year overall survival rates (Gimenes-Teixeira et al., 2013).

More recent publications involving more patients and deeper sequencing techniques, showed that molecular genetic subtypes of human T-ALL display also unique microRNA expression signatures (Wallaert et al., 2017). Moreover, distinct molecular signatures on a transcriptomic and epigenetic level (microRNAs) can differentiate infant from childhood T-ALL (Doerrenberg et al., 2017).

Many miRNAs have been found over-expressed in different tumors, functioning as oncogenes, and for that reason called oncomiRs (Calin et al., 2004; He et al., 2005; Valencia-Sanchez et al., 2006). OncomiRs generally promote tumor development by negatively inhibiting tumor suppressor genes and/or genes that control cell differentiation or apoptosis. In fact, the ablation of Dicer1 – an essential component of the MicroRNA biogenesis machinery (Cobb et al., 2006) – prevents the development and maintenance of Notch-driven T-ALL (Junker et al., 2015). Deletion of Dicer promoted apoptosis in T-ALL cells which is, in part, mediated by miR-21 and its target Pdcd4 (programmed cell death 4) (Junker et al., 2015). Notably, the most highly expressed set of miRNAs in human T-ALL was defined (miR-223, -19b, −20a, −92, -142-3p, −150, −93, −26a, −16 and miR-342) and tested in a mouse model of Notch1-induced T-ALL. The conclusion was that highly expressed miRNAs behave as oncomiRs and cooperate in regulating key tumor suppressor genes in human T-ALL, namely PTEN, BIM, NF1, FBXW7, IKZF1 and PHF6 (Mavrakis et al., 2011).

Conversely, miRNAs can act as tumor suppressors (Calin et al., 2002; Lim et al., 2005) by negatively regulating proto-oncogenes. For example, Li and colleagues (Li et al., 2011) found that down-regulation of miR-451 and miR-709 – direct repressors of Myc – is a key event during intracellular Notch1 (ICN1)-induced T-ALL in mice. ICN1 promotes the degradation of E2a, a transcriptional activator of miR-451 and miR-709, hence leading to the down-regulation of these miRNAs. In agreement, human T-ALL cells with NOTCH1 activating mutations have decreased miR-451 (miR-709 is not conserved in humans) and increased MYC levels. Later, Sanghvi et al. used differential expression analysis of miRNAs against normal thymocytes, analysis of anti-proliferative effects in vitro and tumor suppressive function in vivo, to identify a network of miRNAs (miR-29, miR-31, miR-150, miR-155, and miR-200) with interconnected tumor suppressive effects in T-ALL (Sanghvi et al., 2014). This work showed that there is a widespread mechanism of oncogene activation in T-ALL via elimination of tumor suppressor miRNA actions.

With no intension of being an exhaustive summary of all microRNAs implicated in T-ALL pathogenesis, this review will focus on some of the most studied ones (Table 1).

Table 1.

Main microRNAs referred in this review, their role in the disease and their validated or predicted targets.

microRNA Expression level Role Target Reference
miR-142-3p OE in T-ALL OncomiR GRa Lv et al. (2012)
miR-146b-5p DR in T-ALL Tumor Supressor miR Correia et al. (2016b)
miR-19 OE in T-ALL OncomiR Bim, Pkraa1, Pten, PP2A Mavrakis et al. (2010)
miR-196b OE in HOXA T-ALL subtype
DR in pediatric T-ALL		 Dependent on the genetic context ERG c-Myc (Bhatia et al., 2011; Coskun et al., 2011)
miR-21 OncomiR in Notch-driven T-ALL Pdcd4 Junker et al. (2015)
miR-222 OE in ETP-ALL OncomiR ETS1 Coskun et al. (2013)
miR-223 OE in T-ALL OncomiR FBXW7 (Correia et al., 2013; Mansour et al., 2013)
miR-26b DR in T-ALL Tumor Supressor miR PIK3CD Yuan et al. (2017)
miR-30a Tumor Supressor miR NOTCH1 NOTCH2 Ortega et al. (2015)
miR-451 DR in NOTCH1mut T-ALL Tumor Supressor miR MYC Sanghvi et al. (2014)
Open in a new tab

OE – overexpressed.

DR – down-regulated.

3. The miR-17-92 microRNA cluster

The human polycistron encoding the miR-17-92 microRNA cluster is located at the chromosome 13q31, a genomic region that is recurrently amplified in lymphomas and other cancers (reviewed in (Dal Bo et al., 2015)). The human miR-17−92 transcript can be processed into seven mature miRNAs (miR-17−5p, −17−3p, −18a, −19a, −20a, −19b, and miR-92). The miRNAs encoded from this cluster are highly expressed in murine lymphocytes, embryonic stem cells and precursors. The expression of theses miRNAs decreases upon maturation during lymphocyte development (Xiao et al., 2008). The genomic region encoding the miR-17-92 cluster is often amplified in human B-cell lymphomas and cooperates with up-regulated c-Myc expression to accelerate the formation of B cell lymphomas in mice (He et al., 2005). Furthermore, increased expression of miR-17−92 in mouse lymphocytes results in the development of a lymphoproliferative disease and autoimmunity, causing the premature death of the mice (Xiao et al., 2008). In T-ALL, this cluster is involved in a genomic rearrangement, the translocation t(13; 14)(q32; q11) with the TCRA/D locus (Mavrakis et al., 2010). MiR-19, the cluster component with highest expression in T-ALL, enhances lymphocyte survival and cooperates to promote leukemogenesis in a mouse model of Notch1-induced T-ALL. In this model, miR-19 targets the pro-apoptotic protein Bim, AMP-activated kinase (Prkaa1), and the tumor suppressors Pten and PP2A, resulting in the overall activation of PI3K signaling. In this way, miR-19 directs a coordinated action to control PI3K signaling to promote lymphocyte survival and leukemogenesis (Mavrakis et al., 2010). The mechanisms of pri-miR-17-92 activation in T-ALL extend beyond the translocation mentioned above and remain to be fully understood. It has been proposed that NK-like homeodomain proteins could stimulate the expression of this polycistron in T-ALL (Nagel et al., 2009).

4. MiR-223

The miR-223, reported as a ‘myeloid’ gene (Fukao et al., 2007), is highly up regulated in T-ALL. It was shown to promote Notch1-driven leukemia at least in part by controlling the E3 ligase FBXW7 (Mavrakis et al., 2011). Moreover, miR-223 is a direct target of NOTCH in human T-ALL cells. The binding of NOTCH to miR-223 promoter region requires NF-kB activation (Kumar et al., 2014). We and others (Correia et al., 2013; Mansour et al., 2013) have shown that TAL1 – a major oncogenic transcription factor involved in T-ALL pathogenesis (reviewed in (Correia et al., 2016a)) - binds upstream of miR-223. This binding occurs in a previously described region containing a conserved proximal genomic element with binding sites for the transcription factor C/EBPα and PU.1 (Fukao et al., 2007). MiR-223 is activated by TAL1 and follows the same pattern of expression along thymocyte development as TAL1 (Pike-Overzet et al., 2007), with high levels in progenitor cells and sharp down-regulation in more differentiated thymocyte subsets (Correia et al., 2013). Enforced expression of miR-223 was able to partially rescue the proliferation inhibition caused by TAL1 knockdown, establishing this miRNA as a functional downstream effector of TAL1 in T-ALL cells (Mansour et al., 2013). In this study the link between TAL1 and FBXW7 down-regulation, mediated by miR-223, was firmly established as a mechanism leading to down-regulation of FBXW7 in the majority of T-ALL cases that lack gene-specific FBXW7 inactivating mutations or deletions (Mansour et al., 2013). FBXW7 targets to degradation other oncogenic proteins, such as c-MYC, MYB, cyclin E, mTOR, HIF-1 and MCL-1 (Wang et al., 2012). The oncogene MYB, known to be involved in malignant hematopoiesis (Lahortiga et al., 2007), is also a direct target of TAL1 (Sanda et al., 2012). Given that FBXW7 targets MYB to degradation and that TAL1 might down-regulate FBXW7 through miR-223, it is tempting to speculate that TAL1 may regulate MYB expression levels not only transcriptionally (Sanda et al., 2012) but also at the level of protein stability through a miR-223/FBXW7 axis. In addition, the oncogenic role of miR-223 in T-ALL may extend beyond FBXW7 and involve the potential down-regulation of targets such as E2F1, FOXO1, RHOB or EPB41L3, which have been associated with induction of apoptosis and/or have tumor suppressor roles (Correia et al., 2013).

5. MiR-142-3p

miR-142-3p was initially identified as a specific microRNA for hematopoietic cells (Chen et al., 2004; Landgraf et al., 2007). It is highly expressed in pediatric ALL samples, particularly in T-ALL cells as compared with healthy donor T-cells (Schotte et al., 2009) and especially in T-ALL cells from patients with poor prognosis ((Schotte et al., 2011) Importantly, miR-142-3p stands out as an example of the essential role that a single miRNA can play in leukemia progression, chemotherapeutic resistance and prognosis. In T-ALL, miR-142-3p was shown to promote leukemic cell growth and to induce resistance to glucocorticoid (GC) treatment (Lv et al., 2012). In addition, ectopic expression of miR-142-3p results in the increased proliferation of T-ALL cells without affecting apoptosis. This miRNA specifically targets the cAMP/PKA pathway and glucocorticoid receptor alpha (GRa) and, importantly, T-ALL cells from patients with poor response to prednisolone are sensitized to cell death induced by dexamethasone after down-modulation of miR-142-3p (Lv et al., 2012).

6. MiR-196b

The role of some miRNAs in leukemia is still controversial since it may depend on the cellular context. For instance, miR-196b is highly expressed in T-ALL patient samples as compared to B-ALL (Schotte et al., 2009). In pediatric patients, miR-196b is highly co-expressed with genes from the HOXA cluster, namely in T-ALL cases characterized by the activation of HOXA genes, suggesting co-transcriptional activation (Schotte et al., 2010). The over-expression of this miRNA in mouse bone marrow cells leads to increased proliferative capacity and survival, pointing to a role in leukemogenesis (Coskun et al., 2011). In contrast, it was reported that miR-196b can down-regulate the oncogenic transcription factor ERG in adult AML and T-ALL patients. This hints on the possibility that, instead of promoting leukemogenesis, miR-196b may inhibit this process in some circumstances. In line with this, miR-196b was found down-modulated in pediatric T-ALL patients with respect to normal cells, which suggests a possible tumor suppressor function for this miRNA also in childhood T-ALL (Bhatia et al., 2011). In contrast to what was previously found in B-ALL, c-Myc expression is not down-regulated by miR-196b in T-ALL. Interestingly, miR-196b loses its ability to down-regulate c-Myc expression in T-ALL as a result of mutations in the target 3′UTR of c-Myc, pointing again to a possible tumor suppressive role in this disease. This microRNA may therefore have a dual role in leukemia, depending on the genetic context (Bhatia et al., 2011).

7. Other miRs with impact in T-ALL

Other microRNAs implicated in T-ALL include for instance miR-146b-5p, a tumor suppressor miRNA downregulated by TAL1 (Correia et al., 2016c) and involved in T-cell migration (Correia et al., 2016b; Tu et al., 2019); the miR-30a - transcriptionally suppressed by MYC and a direct inhibitor of NOTCH1 and NOTCH2 expression – mediates a regulatory circuitry that modulate the oncogenic signals of these T-ALL drivers (Ortega et al., 2015); miR-125b causes the malignant transformation of different hematopoietic lineages, leading to B-ALL, T-ALL, or myeloproliferative neoplasms (Bousquet et al., 2010). Recently this microRNA was shown to be activated by TLX3 in the TLX3-subtype of T-ALL (Renou et al., 2017); miR-26b, another tumor suppressor, is an inhibitor of the PI3K/AKT pathway via the targeting of PIK3CD. MiR-26 expression is promoted by PTEN – another inhibitor of the pathway - by an unknown mechanism that involves the differential regulation of isoforms of the transcription factor Ikaros (Yuan et al., 2017); miR-181a – encoded by the miR-181ab1 gene – contributes to the maintenance of Notch oncogenic signals in T-ALL by diminishing Notch negative feedbacks (mediated for instance by Nrarp) and potentiating pre-TCR signals (Fragoso et al., 2012). The deletion of miR-181ab1 gene has no significant impact on normal development, making miR-181a an interesting therapeutic target to inhibit oncogenic signals as alternative to the targeting of oncogenes themselves (Fragoso et al., 2012).

8. Conclusion

Since microRNAs were discovered, around 25 years ago, we have understood their biogenesis, the mechanisms how they regulate mRNA stability and protein translation and their importance in normal development and physiology. We have also started to appreciate the importance of their deregulation in the genesis and development of malignancy. Many, if not most, protein-coding transcripts are potential targets for miRNA regulation (Lewis et al., 2005). An additional layer of complexity is added by the fact that one miRNA is able to target many transcripts of genes often with related functions. Furthermore, several individual transcripts can be targeted by numerous miRNAs that are often regulated together. Integration of data from the miRnome with the transcriptome and proteome will be fundamental for a more comprehensive analysis of the consequences of disrupting the cellular architecture sustained by microRNAs. This obviously requires broad and large cohorts of patients and appropriate healthy tissue, which is a challenge for a rare disease like T-ALL. Nevertheless, miRNAs are not only very interesting biomarkers for various diseases, including T-ALL, but also their tissue specificity makes them attractive candidates for targeted therapy.

9. Conflicts of interest

The authors have not conflict of interest to disclose.

Acknowledgments

We thank Rita Fragoso for valuable feedback. Publication costs of this work were by supported by project UID/BIM/50005/2019, funded by Fundação para a Ciência e a Tecnologia (FCT)/Ministério da Ciência, Tecnologia e Ensino Superior (MCTES), Portugal, through Fundos do Orçamento de Estado. The work conducted in JTB's lab is supported by the consolidator grant ERC CoG-648455 from the European Research Council, under the European Union's Horizon 2020 research and innovation programme, and the FAPESP/20015/2014 and PTDC/MEC-HEM/31588/2017 grants from Fundação para a Ciência e a Tecnologia (FCT)/Ministério da Ciência, Tecnologia e Ensino Superior (MCTES), Portugal.

Contributor Information

Nádia C. Correia, Email: n.correia@dkfz-heidelberg.de.

João T. Barata, Email: joao_barata@medicina.ulisboa.pt.

References

  1. Atak Z.K., Gianfelici V., Hulselmans G., De Keersmaecker K., Devasia A.G., Geerdens E., Mentens N., Chiaretti S., Durinck K., Uyttebroeck A., Vandenberghe P., Wlodarska I., Cloos J., Foa R., Speleman F., Cools J., Aerts S. Comprehensive analysis of transcriptome variation uncovers known and novel driver events in T-cell acute lymphoblastic leukemia. PLoS Genet. 2013;9(12) doi: 10.1371/journal.pgen.1003997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bains T., Heinrich M.C., Loriaux M.M., Beadling C., Nelson D., Warrick A., Neff T.L., Tyner J.W., Dunlap J., Corless C.L., Fan G. Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia. Leukemia. 2012;26(9):2144–2146. doi: 10.1038/leu.2012.74. [DOI] [PubMed] [Google Scholar]
  3. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–297. doi: 10.1016/s0092-8674(04)00045-5. [DOI] [PubMed] [Google Scholar]
  4. Belver L., Ferrando A. The genetics and mechanisms of T cell acute lymphoblastic leukaemia. Nat. Rev. Cancer. 2016;16(8):494–507. doi: 10.1038/nrc.2016.63. [DOI] [PubMed] [Google Scholar]
  5. Bhatia S., Kaul D., Varma N. Functional genomics of tumor suppressor miR-196b in T-cell acute lymphoblastic leukemia. Mol. Cell. Biochem. 2011;346(1–2):103–116. doi: 10.1007/s11010-010-0597-0. [DOI] [PubMed] [Google Scholar]
  6. Bousquet M., Harris M.H., Zhou B., Lodish H.F. MicroRNA miR-125b causes leukemia. Proc. Natl. Acad. Sci. U. S. A. 2010;107(50):21558–21563. doi: 10.1073/pnas.1016611107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Calin G.A., Dumitru C.D., Shimizu M., Bichi R., Zupo S., Noch E., Aldler H., Rattan S., Keating M., Rai K., Rassenti L., Kipps T., Negrini M., Bullrich F., Croce C.M. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. 2002;99(24):15524–15529. doi: 10.1073/pnas.242606799. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Calin G.A., Sevignani C., Dumitru C.D., Hyslop T., Noch E., Yendamuri S., Shimizu M., Rattan S., Bullrich F., Negrini M., Croce C.M. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. U.S.A. 2004;101(9):2999–3004. doi: 10.1073/pnas.0307323101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Chen C.Z., Li L., Lodish H.F., Bartel D.P. MicroRNAs modulate hematopoietic lineage differentiation. Science. 2004;303(5654):83–86. doi: 10.1126/science.1091903. [DOI] [PubMed] [Google Scholar]
  10. Clappier E., Cuccuini W., Cayuela J.M., Vecchione D., Baruchel A., Dombret H., Sigaux F., Soulier J. Cyclin D2 dysregulation by chromosomal translocations to TCR loci in T-cell acute lymphoblastic leukemias. Leukemia. 2006;20(1):82–86. doi: 10.1038/sj.leu.2404008. [DOI] [PubMed] [Google Scholar]
  11. Cobb B.S., Hertweck A., Smith J., O'Connor E., Graf D., Cook T., Smale S.T., Sakaguchi S., Livesey F.J., Fisher A.G., Merkenschlager M. A role for Dicer in immune regulation. J. Exp. Med. 2006;203(11):2519–2527. doi: 10.1084/jem.20061692. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Correia N.C., Arcangeli M.L., Pflumio F., Barata J.T. Stem Cell Leukemia: how a TALented actor can go awry on the hematopoietic stage. Leukemia. 2016;30(10):1968–1978. doi: 10.1038/leu.2016.169. [DOI] [PubMed] [Google Scholar]
  13. Correia N.C., Durinck K., Leite A.P., Ongenaert M., Rondou P., Speleman F., Enguita F.J., Barata J.T. Novel TAL1 targets beyond protein-coding genes: identification of TAL1-regulated microRNAs in T-cell acute lymphoblastic leukemia. Leukemia. 2013;27(7):1603–1606. doi: 10.1038/leu.2013.63. [DOI] [PubMed] [Google Scholar]
  14. Correia N.C., Fragoso R., Carvalho T., Enguita F.J., Barata J.T. MiR-146b negatively regulates migration and delays progression of T-cell acute lymphoblastic leukemia. Sci. Rep. 2016;6:31894. doi: 10.1038/srep31894. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Correia N.C., Melao A., Povoa V., Sarmento L., Gomez de Cedron M., Malumbres M., Enguita F.J., Barata J.T. microRNAs regulate TAL1 expression in T-cell acute lymphoblastic leukemia. Oncotarget. 2016;7(7):8268–8281. doi: 10.18632/oncotarget.6987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Coskun E., Neumann M., Schlee C., Liebertz F., Heesch S., Goekbuget N., Hoelzer D., Baldus C.D. MicroRNA profiling reveals aberrant microRNA expression in adult ETP-ALL and functional studies implicate a role for miR-222 in acute leukemia. Leuk. Res. 2013;37(6):647–656. doi: 10.1016/j.leukres.2013.02.019. [DOI] [PubMed] [Google Scholar]
  17. Coskun E., von der Heide E.K., Schlee C., Kühnl A., Gökbuget N., Hoelzer D., Hofmann W.-K., Thiel E., Baldus C.D. The role of microRNA-196a and microRNA-196b as ERG regulators in acute myeloid leukemia and acute T-lymphoblastic leukemia. Leuk. Res. 2011;35(2):208–213. doi: 10.1016/j.leukres.2010.05.007. [DOI] [PubMed] [Google Scholar]
  18. Dal Bo M., Bomben R., Hernandez L., Gattei V. The MYC/miR-17-92 axis in lymphoproliferative disorders: a common pathway with therapeutic potential. Oncotarget. 2015;6(23):19381–19392. doi: 10.18632/oncotarget.4574. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Doerrenberg M., Kloetgen A., Hezaveh K., Wossmann W., Bleckmann K., Stanulla M., Schrappe M., McHardy A.C., Borkhardt A., Hoell J.I. T-cell acute lymphoblastic leukemia in infants has distinct genetic and epigenetic features compared to childhood cases. Genes Chromosomes Cancer. 2017;56(2):159–167. doi: 10.1002/gcc.22423. [DOI] [PubMed] [Google Scholar]
  20. Fabbri M., Croce C.M., Calin G.A. MicroRNAs in the ontogeny of leukemias and lymphomas. Leuk. Lymphoma. 2009;50(2):160–170. doi: 10.1080/10428190802535114. [DOI] [PubMed] [Google Scholar]
  21. Ferrando A.A., Neuberg D.S., Staunton J., Loh M.L., Huard C., Raimondi S.C., Behm F.G., Pui C.-H., Downing J.R., Gilliland D.G., Lander E.S., Golub T.R., Look A.T. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002;1(1):75–87. doi: 10.1016/s1535-6108(02)00018-1. [DOI] [PubMed] [Google Scholar]
  22. Fragoso R., Mao T., Wang S., Schaffert S., Gong X., Yue S., Luong R., Min H., Yashiro-Ohtani Y., Davis M., Pear W., Chen C.Z. Modulating the strength and threshold of NOTCH oncogenic signals by mir-181a-1/b-1. PLoS Genet. 2012;8(8) doi: 10.1371/journal.pgen.1002855. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Fukao T., Fukuda Y., Kiga K., Sharif J., Hino K., Enomoto Y., Kawamura A., Nakamura K., Takeuchi T., Tanabe M. An evolutionarily conserved mechanism for microRNA-223 expression revealed by microRNA gene profiling. Cell. 2007;129(3):617–631. doi: 10.1016/j.cell.2007.02.048. [DOI] [PubMed] [Google Scholar]
  24. Fulci V., Colombo T., Chiaretti S., Messina M., Citarella F., Tavolaro S., Guarini A., Foà R., Macino G. Characterization of B- and T-lineage acute lymphoblastic leukemia by integrated analysis of MicroRNA and mRNA expression profiles. Genes Chromosomes Cancer. 2009;48(12):1069–1082. doi: 10.1002/gcc.20709. [DOI] [PubMed] [Google Scholar]
  25. Gimenes-Teixeira H.L., Lucena-Araujo A.R., Dos Santos G.A., Zanette D.L., Scheucher P.S., Oliveira L.C., Dalmazzo L.F., Silva-Junior W.A., Falcao R.P., Rego E.M. Increased expression of miR-221 is associated with shorter overall survival in T-cell acute lymphoid leukemia. Exp. Hematol. Oncol. 2013;2(1):10. doi: 10.1186/2162-3619-2-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Graux C., Cools J., Michaux L., Vandenberghe P., Hagemeijer A. Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast. Leukemia. 2006;20(9):1496–1510. doi: 10.1038/sj.leu.2404302. [DOI] [PubMed] [Google Scholar]
  27. Han B.W., Feng D.D., Li Z.G., Luo X.Q., Zhang H., Li X.J., Zhang X.J., Zheng L.L., Zeng C.W., Lin K.Y., Zhang P., Xu L., Chen Y.Q. A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL. Hum. Mol. Genet. 2011;20(24):4903–4915. doi: 10.1093/hmg/ddr428. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. He L., Thomson J.M., Hemann M.T., Hernando-Monge E., Mu D., Goodson S., Powers S., Cordon-Cardo C., Lowe S.W., Hannon G.J., Hammond S.M. A microRNA polycistron as a potential human oncogene. Nature. 2005;435(7043):828–833. doi: 10.1038/nature03552. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Hebert J., C J.M., B J., S F. Candidate tumor-suppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias [see comments] Blood. 1994;84(12):4038–4044. [PubMed] [Google Scholar]
  30. Homminga I., Pieters R., Langerak Anton W., de Rooi, Johan J., Stubbs A., Verstegen M., Vuerhard M., Buijs-Gladdines J., Kooi C., Klous P., van Vlierberghe P., Ferrando Adolfo A., Cayuela Jean M., Verhaaf B., Beverloo H.B., Horstmann M., de Haas V., Wiekmeijer A.-S., Pike-Overzet K., Staal Frank J.T., de Laat W., Soulier J., Sigaux F., Meijerink Jules P.P. Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. Cancer Cell. 2011;19(4):484–497. doi: 10.1016/j.ccr.2011.02.008. [DOI] [PubMed] [Google Scholar]
  31. Junker F., Chabloz A., Koch U., Radtke F. Dicer1 imparts essential survival cues in Notch-driven T-ALL via miR-21-mediated tumor suppressor Pdcd4 repression. Blood. 2015;126(8):993–1004. doi: 10.1182/blood-2014-12-618892. [DOI] [PubMed] [Google Scholar]
  32. Kumar V., Palermo R., Talora C., Campese A.F., Checquolo S., Bellavia D., Tottone L., Testa G., Miele E., Indraccolo S., Amadori A., Ferretti E., Gulino A., Vacca A., Screpanti I. 2014. Notch and NF-kB Signaling Pathways Regulate miR-223/FBXW7 axis in T-Cell Acute Lymphoblastic Leukemia. (Leukemia) [DOI] [PubMed] [Google Scholar]
  33. Lahortiga I., De Keersmaecker K., Van Vlierberghe P., Graux C., Cauwelier B., Lambert F., Mentens N., Beverloo H.B., Pieters R., Speleman F., Odero M.D., Bauters M., Froyen G., Marynen P., Vandenberghe P., Wlodarska I., Meijerink J.P., Cools J. Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat. Genet. 2007;39(5):593–595. doi: 10.1038/ng2025. [DOI] [PubMed] [Google Scholar]
  34. Landgraf P., Rusu M., Sheridan R., Sewer A., Iovino N., Aravin A., Pfeffer S., Rice A., Kamphorst A.O., Landthaler M., Lin C., Socci N.D., Hermida L., Fulci V., Chiaretti S., Foa R., Schliwka J., Fuchs U., Novosel A., Muller R.U., Schermer B., Bissels U., Inman J., Phan Q., Chien M., Weir D.B., Choksi R., De Vita G., Frezzetti D., Trompeter H.I., Hornung V., Teng G., Hartmann G., Palkovits M., Di Lauro R., Wernet P., Macino G., Rogler C.E., Nagle J.W., Ju J., Papavasiliou F.N., Benzing T., Lichter P., Tam W., Brownstein M.J., Bosio A., Borkhardt A., Russo J.J., Sander C., Zavolan M., Tuschl T. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell. 2007;129(7):1401–1414. doi: 10.1016/j.cell.2007.04.040. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15–20. doi: 10.1016/j.cell.2004.12.035. [DOI] [PubMed] [Google Scholar]
  36. Li X., Sanda T., Look A.T., Novina C.D., von Boehmer H. Repression of tumor suppressor miR-451 is essential for NOTCH1-induced oncogenesis in T-ALL. J. Exp. Med. 2011;208(4):663–675. doi: 10.1084/jem.20102384. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Lim L.P., Lau N.C., Garrett-Engele P., Grimson A., Schelter J.M., Castle J., Bartel D.P., Linsley P.S., Johnson J.M. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005;433(7027):769–773. doi: 10.1038/nature03315. [DOI] [PubMed] [Google Scholar]
  38. Lu J., Getz G., Miska E.A., Alvarez-Saavedra E., Lamb J., Peck D., Sweet-Cordero A., Ebert B.L., Mak R.H., Ferrando A.A., Downing J.R., Jacks T., Horvitz H.R., Golub T.R. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834–838. doi: 10.1038/nature03702. [DOI] [PubMed] [Google Scholar]
  39. Lv M., Zhang X., Jia H., Li D., Zhang B., Zhang H., Hong M., Jiang T., Jiang Q., Lu J., Huang X., Huang B. An oncogenic role of miR-142-3p in human T-cell acute lymphoblastic leukemia (T-ALL) by targeting glucocorticoid receptor-[alpha] and cAMP/PKA pathways. Leukemia. 2012;26(4):769–777. doi: 10.1038/leu.2011.273. [DOI] [PubMed] [Google Scholar]
  40. Mansour M.R., Sanda T., Lawton L.N., Li X., Kreslavsky T., Novina C.D., Brand M., Gutierrez A., Kelliher M.A., Jamieson C.H., von Boehmer H., Young R.A., Look A.T. The TAL1 complex targets the FBXW7 tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia. J. Exp. Med. 2013;210(8):1545–1557. doi: 10.1084/jem.20122516. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Mavrakis K.J., Van Der Meulen J., Wolfe A.L., Liu X., Mets E., Taghon T., Khan A.A., Setty M., Rondou P., Vandenberghe P., Delabesse E., Benoit Y., Socci N.B., Leslie C.S., Van Vlierberghe P., Speleman F., Wendel H.-G. A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL) Nat. Genet. 2011;43(7):673–678. doi: 10.1038/ng.858. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Mavrakis K.J., Wolfe A.L., Oricchio E., Palomero T., de Keersmaecker K., McJunkin K., Zuber J., James T., Khan A.A., Leslie C.S., Parker J.S., Paddison P.J., Tam W., Ferrando A., Wendel H.-G. Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia. Nat. Cell Biol. 2010;12(4):372–379. doi: 10.1038/ncb2037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Mi S., Lu J., Sun M., Li Z., Zhang H., Neilly M.B., Wang Y., Qian Z., Jin J., Zhang Y., Bohlander S.K., Le Beau M.M., Larson R.A., Golub T.R., Rowley J.D., Chen J. MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc. Natl. Acad. Sci. 2007;104(50):19971–19976. doi: 10.1073/pnas.0709313104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Nagel S., Venturini L., Przybylski G.K., Grabarczyk P., Schmidt C.A., Meyer C., Drexler H.G., Macleod R.A., Scherr M. Activation of miR-17-92 by NK-like homeodomain proteins suppresses apoptosis via reduction of E2F1 in T-cell acute lymphoblastic leukemia. Leuk. Lymphoma. 2009;50(1):101–108. doi: 10.1080/10428190802626632. [DOI] [PubMed] [Google Scholar]
  45. Oliveira M.L., Akkapeddi P., Alcobia I., Almeida A.R., Cardoso B.A., Fragoso R., Serafim T.L., Barata J.T. From the outside, from within: biological and therapeutic relevance of signal transduction in T-cell acute lymphoblastic leukemia. Cell. Signal. 2017;38:10–25. doi: 10.1016/j.cellsig.2017.06.011. [DOI] [PubMed] [Google Scholar]
  46. Oliveira M.L., Akkapeddi P., Ribeiro D., Melao A., Barata J.T. IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia: an update. Adv Biol Regul. 2019;71:88–96. doi: 10.1016/j.jbior.2018.09.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Ortega M., Bhatnagar H., Lin A.P., Wang L., Aster J.C., Sill H., Aguiar R.C. A microRNA-mediated regulatory loop modulates NOTCH and MYC oncogenic signals in B- and T-cell malignancies. Leukemia. 2015;29(4):968–976. doi: 10.1038/leu.2014.302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Pekarsky Y., Croce C.M. Noncoding RNA genes in cancer pathogenesis. Advances in Biological Regulation. 2019;71:219–223. doi: 10.1016/j.jbior.2018.12.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Pike-Overzet K., de Ridder D., Weerkamp F., Baert M.R., Verstegen M.M., Brugman M.H., Howe S.J., Reinders M.J., Thrasher A.J., Wagemaker G., van Dongen J.J., Staal F.J. Ectopic retroviral expression of LMO2, but not IL2Rgamma, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy. Leukemia. 2007;21(4):754–763. doi: 10.1038/sj.leu.2404563. [DOI] [PubMed] [Google Scholar]
  50. Pui C.H., Evans W.E. A 50-year journey to cure childhood acute lymphoblastic leukemia. Semin. Hematol. 2013;50(3):185–196. doi: 10.1053/j.seminhematol.2013.06.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Pui C.H., Relling M.V., Downing J.R. Acute lymphoblastic leukemia. N. Engl. J. Med. 2004;350(15):1535–1548. doi: 10.1056/NEJMra023001. [DOI] [PubMed] [Google Scholar]
  52. Renou L., Boelle P.Y., Deswarte C., Spicuglia S., Benyoucef A., Calvo J., Uzan B., Belhocine M., Cieslak A., Landman-Parker J., Baruchel A., Asnafi V., Pflumio F., Ballerini P., Naguibneva I. Homeobox protein TLX3 activates miR-125b expression to promote T-cell acute lymphoblastic leukemia. Blood Adv. 2017;1(12):733–747. doi: 10.1182/bloodadvances.2017005538. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Sanda T., Lawton Lee N., Barrasa M.I., Fan Zi P., Kohlhammer H., Gutierrez A., Ma W., Tatarek J., Ahn Y., Kelliher Michelle A., Jamieson Catriona H.M., Staudt Louis M., Young Richard A., Look A.T. Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia. Cancer Cell. 2012;22(2):209–221. doi: 10.1016/j.ccr.2012.06.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Sanghvi V.R., Mavrakis K.J., Van der Meulen J., Boice M., Wolfe A.L., Carty M., Mohan P., Rondou P., Socci N.D., Benoit Y., Taghon T., Van Vlierberghe P., Leslie C.S., Speleman F., Wendel H.G. Characterization of a set of tumor suppressor microRNAs in T cell acute lymphoblastic leukemia. Sci. Signal. 2014;7(352):ra111. doi: 10.1126/scisignal.2005500. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Schotte D., Chau J.C., Sylvester G., Liu G., Chen C., van der Velden V.H., Broekhuis M.J., Peters T.C., Pieters R., den Boer M.L. Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia. Leukemia. 2009;23(2):313–322. doi: 10.1038/leu.2008.286. [DOI] [PubMed] [Google Scholar]
  56. Schotte D., De Menezes R.X., Akbari Moqadam F., Mohammadi Khankahdani L., Lange-Turenhout E., Chen C., Pieters R., Den Boer M.L. MicroRNAs characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia. Haematologica. 2011;96(5):703–711. doi: 10.3324/haematol.2010.026138. Epub 2011 Jan 17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Schotte D., Lange-Turenhout E.A., Stumpel D.J., Stam R.W., Buijs-Gladdines J.G., Meijerink J.P., Pieters R., Den Boer M.L. Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia. Haematologica. 2010;95(10):1675–1682. doi: 10.3324/haematol.2010.023481. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Tu Z., Xiong J., Xiao R., Shao L., Yang X., Zhou L., Yuan W., Wang M., Yin Q., Wu Y., Pan S., Leng J., Jiang D., He C., Zhang Q. Loss of miR-146b-5p promotes T cell acute lymphoblastic leukemia migration and invasion via the IL-17A pathway. J. Cell. Biochem. 2019;120(4):5936–5948. doi: 10.1002/jcb.27882. [DOI] [PubMed] [Google Scholar]
  59. Valencia-Sanchez M.A., Liu J., Hannon G.J., Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 2006;20(5):515–524. doi: 10.1101/gad.1399806. [DOI] [PubMed] [Google Scholar]
  60. Wallaert A., Van Loocke W., Hernandez L., Taghon T., Speleman F., Van Vlierberghe P. Comprehensive miRNA expression profiling in human T-cell acute lymphoblastic leukemia by small RNA-sequencing. Sci. Rep. 2017;7(1):7901. doi: 10.1038/s41598-017-08148-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Wang Z., Inuzuka H., Zhong J., Wan L., Fukushima H., Sarkar F.H., Wei W. Tumor suppressor functions of FBW7 in cancer development and progression. FEBS Lett. 2012;586(10):1409–1418. doi: 10.1016/j.febslet.2012.03.017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Weng A.P., Ferrando A.A., Lee W., Morris J.P.t., Silverman L.B., Sanchez-Irizarry C., Blacklow S.C., Look A.T., Aster J.C. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306(5694):269–271. doi: 10.1126/science.1102160. [DOI] [PubMed] [Google Scholar]
  63. Xiao C., Srinivasan L., Calado D.P., Patterson H.C., Zhang B., Wang J., Henderson J.M., Kutok J.L., Rajewsky K. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat. Immunol. 2008;9(4):405–414. doi: 10.1038/ni1575. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Yuan T., Yang Y., Chen J., Li W., Li W., Zhang Q., Mi Y., Goswami R.S., You J.Q., Lin D., Qian M.D., Calin S., Liang Y., Miranda R.N., Calin G.A., Zhou X., Ma L., Zweidler-McKay P.A., Liu B., Weng A.P., Medeiros L.J., Zhang Y., You M.J. Regulation of PI3K signaling in T-cell acute lymphoblastic leukemia: a novel PTEN/Ikaros/miR-26b mechanism reveals a critical targetable role for PIK3CD. Leukemia. 2017;31(11):2355–2364. doi: 10.1038/leu.2017.80. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Zhang H., Luo X.Q., Zhang P., Huang L.B., Zheng Y.S., Wu J., Zhou H., Qu L.H., Xu L., Chen Y.Q. MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia. PLoS One. 2009;4(11) doi: 10.1371/journal.pone.0007826. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES